ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical data shows that CML patients whose blood cells have mutations in TET2 and ASXL1, some of which may exist prior to development of CML, frequently exhibit a poor response to TKI therapy (Kim et al., 2017; Marum et al., 2017).